Targeting mTOR network in colorectal cancer therapy

Area of Science:

• Oncology
• Molecular Biology
• Cancer Therapeutics

Background:

• The mechanistic target of rapamycin (mTOR) pathway is crucial for cell growth and proliferation, integrating nutrient and growth factor signals.
• Colorectal cancer (CRC) involves multiple genetic alterations, including hyperactivation of pathways that converge on mTOR.
• mTOR pathway dysregulation is implicated in CRC development and progression, making it a therapeutic target.

Purpose of the Study:

• To systematically summarize oncogenic gene alterations in colorectal cancer and their interaction with the mTOR pathway.
• To review recent preclinical and clinical therapeutic strategies targeting the mTOR pathway in CRC.
• To discuss novel therapeutic agents and their potential in modulating mTOR signaling for CRC treatment.

Main Methods:

• Literature review of preclinical and clinical studies on mTOR pathway in colorectal cancer.
• Systematic summary of genetic alterations in CRC and their link to mTOR signaling.
• Analysis of combination therapy approaches and emerging therapeutic agents targeting mTOR.

Main Results:

• While single-agent mTOR inhibitors have shown modest responses in CRC, combination therapies are promising.
• Targeting the mTOR pathway in CRC has demonstrated potential in preclinical and in vitro studies.
• New agents like NSAIDs and metformin are being investigated for their therapeutic potential in modulating mTOR signaling.

Conclusions:

• The mTOR pathway is a significant target for colorectal cancer therapy, but monotherapy has limitations.
• Combination regimens involving mTOR inhibitors with other agents show promise for improved efficacy in advanced CRC.
• Further elucidation of mTOR signaling mechanisms is essential for developing optimized and effective therapeutic strategies for colorectal cancer.